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Introduction
Bovine	respiratory	disease	continues	to	be	the	most	costly	disease	affecting	produc-
tivity	and	profitability	in	the	stocker	segment.	Long-acting	injectable	antimicrobials	
are	presently	used	to	reduce	the	incidence	and	severity	of	bovine	respiratory	disease.	
However,	future	use	of	antimicrobial	treatment	may	be	significantly	curtailed	in	light	
of	an	increasing	negative	perception	of	antibiotic	usage	in	food	animals	by	consumers	
and	governmental	agencies.	Consequently,	preconditioning	and	enhanced	nutrition	
programs	that	may	include	nutraceuticals	could	become	more	prevalent.	MorindaMax	
(Morinda	International,	Provo,	UT)	is	a	natural	product	manufactured	from	the	
Morinda citrifolia	fruit	(i.e.,	Noni).	Published	literature	suggests	this	plant	extract	has	a	
broad	range	of	immune-enhancing	effects,	including	antibacterial,	anti-inflammatory,	
analgesic,	antioxidant,	and	anti-tumor	effects.
Experimental Procedures
A	42-day	receiving	study	was	conducted	at	the	Kansas	State	University	Beef	Stocker	
Unit	during	March	2009	to	evaluate	dry	matter	intake	and	health	parameters	of	
high-risk	stocker	calves	receiving	Morinda citrifolia.	All	cattle	were	sourced	from	an	
order	buyer	in	Tennessee,	and	cattle	were	received	over	3	consecutive	days	(one	load	
per	day).	Upon	arrival,	all	calves	were	weighed,	tagged,	mass	medicated	with	Excede	
(Pfizer	Animal	Health,	New	York,	NY)	at	1.5	mL/100	lb	body	weight	and	palpated	
for	gender	(bull	or	steer).	Calves	were	then	given	ad	libitum	access	to	long-stem	prairie	
hay	and	water	overnight.	The	following	day,	calves	were	vaccinated	against	clostridial	
and	respiratory	diseases	and	dewormed,	and	bulls	were	surgically	castrated.	Each	load	
was	blocked	by	arrival	date	and	randomly	assigned	to	one	of	three	treatments	for	a	total	
of	24	pens.	Castrated	bulls	were	equally	distributed	among	the	eight	pens	within	each	
load.	Cattle	were	weighed	and	revaccinated	14	days	after	initial	processing	and	weighed	
again	following	the	42-day	feeding	period.	Calves	were	stepped	up	using	three	sequen-
tial	growing	diets	ranging	from	29%	to	36.5%	concentrate.	Diets	were	fed	twice	daily,	
and	one	of	the	following	treatments	was	top-dressed	on	the	delivered	feed	for	10	days	
starting	on	day	2	after	arrival:	water	at	4	oz/head	per	day	(control),	MorindaMax	at		
2	oz/head	per	day	(low),	or	MorindaMax	at	4	oz/head	per	day	(high).
Cattle	were	observed	daily	for	symptoms	of	bovine	respiratory	disease	and	injury	(scro-
tal	infections,	lameness,	etc.)	by	personnel	blinded	to	treatments.	Following	a	morato-
rium	of	3	days	post-metaphylaxis,	calves	were	pulled	and	treated	for	respiratory	disease	
as	needed.	Calves	determined	to	need	treatment	were	given	Baytril	(Bayer	Animal	
Health,	Shawnee	Mission,	KS)	at	5	mL/100	lb	body	weight	as	a	first	treatment,	Nuflor	
(Intervet/Schering-Plough	Animal	Health,	Millsboro,	DE)	at	6	mL/100	lb	body	weight	
as	a	second	treatment,	and	Bio-Mycin	200	(Boehringer	Ingelheim,	Ridgefield,	CT)	at	
4.5	mL/100	lb	body	weight	as	a	third	treatment,	if	needed.
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Bunks	were	checked	twice	daily,	and	feed	was	delivered	in	amounts	sufficient	to	result	
in	slick	bunks	both	morning	and	afternoon.	Calves	were	fed	their	respective	diets	at	
approximately	7:00	a.m.	and	3:00	p.m.	daily	for	55	days.
Daily	dry	matter	intake,	gains,	and	feed	efficiencies	were	determined	for	each	pen	
of	calves.	Health	records	were	used	to	determine	the	number	of	animals	treated	and	
percentage	of	death	loss.	
Performance	and	health	data	were	analyzed	by	using	the	random	effects	MIXED	model	
procedure	of	SAS	(SAS	Institute,	Inc.,	Cary,	NC).	Data	were	arranged	in	a	randomized	
incomplete	block	design;	pen	served	as	the	experimental	unit	for	growth	and	health	
outcomes	as	affected	by	treatment.	In	the	model,	fixed	effects	were	treatment,	load,	and	
gender,	and	random	effects	were	load	×	treatment,	pen,	and	animal	ID.	Percentages	of	
bovine	respiratory	disease	morbidity	and	mortality	were	tested	by	using	the	Chi	Square	
test,	and	differences	were	declared	significant	at	P<0.05.	
Results and Discussion
Performance	and	health	results	are	presented	in	Table	1.	Overall,	all	cattle	performed	
exceedingly	well,	and	there	was	little	to	no	health	challenge	from	bovine	respiratory	
disease.	There	were	no	significant	differences	between	treatments	in	the	percentage	of	
steers	treated	once,	twice,	or	three	times	for	bovine	respiratory	disease	(P>0.05).	There	
were	no	significant	differences	in	daily	gain	(P=0.81),	daily	dry	matter	intake	(P=0.34),	
or	feed	efficiency	(P=0.80)	between	the	three	treatments.	Although	there	was	a	slight	
numerical	increase	in	daily	feed	intake	for	MorindaMax	treatment	groups	(low	and	
high)	relative	to	the	control	treatment,	there	were	only	subtle	numerical	differences	in	
average	daily	gain	and	feed	efficiency	between	the	three	treatment	groups.
Implications
The	low	level	of	bovine	respiratory	disease	(as	revealed	by	morbidity	and	mortality	rates)	
was	likely	not	sufficient	to	adequately	test	this	feed	additive.
113
Nutrition
Table 1. Effect of MorindaMax on growth performance and health of calves
Item Control1 Low High SEM2 P-value
Pens	 8 8 8 --- ---
Animals	on	trial	 92 94 94 --- ---
Days	on	feed	 42 42 42 --- ---
Initial	weight,	lb	 488 486 486 --- ---
Final	shrunk	weight,	lb	 617 610 614 --- ---
Day	1	to	13	
Dry	matter	intake,	lb/day	 10.3 10.2 10.5 0.29 0.56
Daily	gain,	lb/day	 3.11 3.12 3.23 0.14 0.81
Feed	efficiency	 3.21 3.22 3.12 0.13 0.86
Day	1	to	27	
Dry	matter	intake,	lb/day	 13.2 13.2 13.6 0.29 0.48
Daily	gain,	lb/day	 3.35 3.35 3.43 0.14 0.79
Feed	efficiency	 3.78 3.79 3.79 0.12 0.99
Day	1	to	42	
Dry	matter	intake,	lb/day	 15.2 15.0 15.7 0.32 0.34
Daily	gain,	lb/day 3.52 3.39 3.48 0.14 0.81
Feed	efficiency 4.18 4.26 4.25 0.10 0.80
Health	status	
Morbidity	by	treatment	group,	%	of	experimental	treatment3	
First	treatment,	%	 10.64 12.77 8.51 --- 0.68
Second	treatment,	%	 3.19 8.51 3.19 --- 0.19
Third	treatment,	%	 1.06 3.19 0 --- 0.33
Miscellaneous	morbidity,	%	of	experimental	treatment	 5.32 3.19 2.13 --- 0.62
Miscellaneous	morbidity,	retreatment,	%	 0 2.13 0 --- 0.33
Mortality,	%	 0 0 0 --- ---
1	Control,	basal	diet	with	4	oz	water	per	day	applied	for	each	animal;	Low,	MorindaMax	at	2	oz/head	per	day	top-dressed	on	feed;	High,	
MorindaMax	at	4	oz/head	per	day	top-dressed	on	feed.	All	treatments	applied	on	days	1	to	10.	
2	Standard	errors	of	the	least	squares	mean,	n	=	11	or	12.	
3	Morbidity	data	reflect	respiratory	data	only.	Miscellaneous	morbidity	data	reflects	infected	scrotums,	pink	eye,	skeletal	problems,	or	any	other	
medical	issue	needing	treatment.	No	mortality	was	observed.
